Weh H J, Agarwal K, Zornig C, Schwarz R, Dietel M, Hossfeld D K
Department of Oncology/Hematology, Medical University Clinic, Hamburg, Federal Republic of Germany.
Cancer Chemother Pharmacol. 1993;31 Suppl 2:S189-93.
Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C). The patients' characteristics were comparable among the three groups. Overall remission rates were 34% in group A, 44% in group B, and 18% in group C. The duration of remission was 10 months and the median survival was 13 months in groups A and B. Toxicity, especially myelotoxicity, was severe, with no marked differences being noted between the groups. We conclude that both doxorubicin/dacarbazine and doxorubicin/ifosfamide are active regimens in metastatic soft-tissue sarcomas; nevertheless, the overall prognosis for these patients remains poor.
1982年至1986年间，38例软组织肉瘤患者接受了阿霉素/达卡巴嗪联合治疗（A组）；1986年至1990年间，另外46例患者接受了阿霉素/异环磷酰胺治疗（B组）；1990年至1991年间，11例患者接受了阿霉素和异环磷酰胺交替治疗方案（C组）。三组患者的特征具有可比性。A组的总缓解率为34%，B组为44%，C组为18%。A组和B组的缓解期为10个月，中位生存期为13个月。毒性，尤其是骨髓毒性严重，各组之间无明显差异。我们得出结论，阿霉素/达卡巴嗪和阿霉素/异环磷酰胺都是转移性软组织肉瘤的有效治疗方案；然而，这些患者的总体预后仍然很差。
